Jaguar Health, Inc. (NASDAQ: JAGX) Reports Q4 2025 and FY 2025 Financial Results

Executive Summary

Jaguar Health, Inc. has published its financial results for the fourth quarter and full year 2025. The report contains several key developments, including a new licensing deal, changes in product revenue, and updates on regulatory compliance that may significantly impact shareholder value. Investors should pay close attention to the following highlights and detailed analysis.

Key Highlights

• Q4 Net Revenue: \$3.2 million, up 5% from Q3 2025, but down 8% from Q4 2024.
• FY 2025 Net Revenue: \$11.5 million, with \$11.2 million from Mytesi and Canalevia-CA1 sales.
• New U.S. License Agreement: In January 2026, Jaguar entered into a U.S. license agreement with Future Pak for Mytesi and Canalevia-CA1, receiving an upfront \$16 million in non-dilutive capital, with an additional \$2 million pending post-closing conditions.
• Milestone Payments: \$3.0 million received from Future Pak, with potential for up to \$20 million in future milestones and payments.
• Nasdaq Compliance: Jaguar faces noncompliance with Nasdaq Listing Rule 5550(a)(2). Delisting proceedings are stayed pending an April 7, 2026 hearing, making this a price-sensitive event for investors.
• Webcast Reminder: Jaguar will host an investor webcast on April 10, 2026 at 8:30 a.m. Eastern to discuss Q4 financials and company updates.

Detailed Financial Analysis

Revenue Performance

• Q4 2025 net revenue totaled \$3.2 million, a modest increase from Q3 2025 (\$3.1 million), but a decrease from Q4 2024 (\$3.5 million).
• FY 2025 net product revenue was \$11.5 million, slightly down from \$11.7 million in FY 2024.
• License revenue for Q4 2025 included \$42,500 from a securities purchase agreement with a European partner. Deferred license revenue as of December 31, 2025 stands at \$552,000.
• Neonorm (non-prescription product) revenues were minimal.

Cost Structure and Expenses

• Cost of Product Revenue: Increased significantly to \$3.8 million in FY 2025 (vs. \$2.0 million in FY 2024), primarily due to a \$2.0 million inventory adjustment.
• Research & Development: R&D expenses rose sharply to \$25.0 million in 2025 (up from \$16.5 million), mainly driven by clinical and manufacturing costs related to crofelemer lyophilization and late-stage trials.
• Sales & Marketing: Increased to \$9.2 million (from \$7.7 million), largely due to personnel and benefits for the Gelclair sales team.
• General & Administrative: Up to \$18.6 million (from \$16.3 million), driven by legal, compliance, printing, investor relations, and financing activities.
• Impairment Loss: \$0.8 million recognized for indefinite-lived intangible assets due to delays in IBS and PEDS programs.

Profitability and Losses

• Loss from Operations: Increased to \$45.9 million in 2025 (up from \$30.8 million in 2024).
• Net Loss: Net loss attributable to common shareholders was \$53.6 million in 2025, up from \$38.5 million in 2024.
• Net Loss Per Share: \$24.27 in 2025 versus \$130.69 in 2024 (due to share count changes).
• Non-GAAP Recurring EBITDA: Net loss of \$48.1 million in 2025 compared to \$35.9 million in 2024.
• Debt Extinguishment: Loss of \$1.8 million in 2025, compared to a gain of \$1.2 million in 2024, due to modifications in royalty interest agreements.
• Fair Value Adjustment: Loss of \$6.3 million in 2025 on financial instruments, down from \$9.5 million in 2024.

Strategic and Regulatory Developments

• Future Pak Licensing Deal: Future Pak will handle all commercial efforts for Mytesi and Canalevia-CA1 in the U.S. Jaguar will supply product at a premium and recognize manufacturing revenue. This transition aligns Jaguar with its strategy to focus on rare-disease intestinal failure indications.
• Prescription Volume Trends: Mytesi prescription volume decreased 3.7% in 2025 vs. 2024, with larger declines seen in Q4 2025 vs. Q3 2025 (5.8%) and Q4 2025 vs. Q4 2024 (12.2%).
• Nasdaq Listing Compliance: Jaguar is appealing a Nasdaq noncompliance determination (Rule 5550(a)(2)) at an April 7, 2026 hearing. Delisting is stayed until a final decision is reached. This is a material risk for shareholders and could lead to share price volatility.

Product Portfolio Updates

• Mytesi: FDA-approved, plant-based antidiarrheal for noninfectious diarrhea in HIV/AIDS patients on ART. Most common adverse reactions: upper respiratory tract infection, bronchitis, cough, flatulence, increased bilirubin.
• Gelclair: Oral gel for pain management of mucositis/stomatitis, ulcers, and oral trauma. No adverse effects reported in clinical trials, rare postmarketing complaints of burning sensation.
• Canalevia-CA1: Conditionally approved for chemotherapy-induced diarrhea in dogs. Not for human use. Most common adverse reactions: decreased appetite, activity, dehydration, abdominal pain, vomiting.

Upcoming Events

• Investor Webcast: Scheduled for April 10, 2026 at 8:30 a.m. Eastern. Investors are encouraged to register for updates on company performance and outlook.

Forward-Looking Statements

The company has issued standard forward-looking statements regarding its Nasdaq appeal and upcoming webcast. Management cautions investors that such statements are subject to risks and uncertainties beyond their control.

Conclusion: Price-Sensitive Takeaways for Investors

• Nasdaq Listing Risk: The appeal outcome regarding Nasdaq compliance could have a significant impact on share price and liquidity.
• Future Pak Deal: Immediate infusion of \$16 million in non-dilutive capital, with potential for additional payments, provides financial stability and strategic shift.
• Rising Losses and Expenses: Substantial increases in operating and net losses, as well as R&D spending, may affect investor sentiment and future funding requirements.
• Prescription Volume Decline: Decreasing volume for Mytesi could indicate market challenges.

Disclaimer: This article is for informational purposes only. It does not constitute financial advice, investment recommendation, or a solicitation to buy or sell securities. Investors should conduct their own due diligence and consult professional advisors before making any investment decisions. The author and publisher accept no liability for any actions taken based on this report.

View Jaguar Health, Inc. Historical chart here